Welcome to our dedicated page for OmniAb SEC filings (Ticker: OABIW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OmniAb's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OmniAb's regulatory disclosures and financial reporting.
OmniAb director Carolyn R. Bertozzi reported equity-based compensation activity. She exercised 20,000 Restricted Stock Units into Common Stock, bringing her direct holdings to 113,308 shares. She also received grants of 40,000 stock options at an exercise price of $2.03 and 20,000 new RSUs, each unit representing one share of Common Stock. The RSUs and options vest in full on the earlier of the next annual stockholder meeting or the first anniversary of their grant date.
OmniAb director Carolyn R. Bertozzi reported equity-based compensation activity. She exercised 20,000 Restricted Stock Units into Common Stock, bringing her direct holdings to 113,308 shares. She also received grants of 40,000 stock options at an exercise price of $2.03 and 20,000 new RSUs, each unit representing one share of Common Stock. The RSUs and options vest in full on the earlier of the next annual stockholder meeting or the first anniversary of their grant date.
OmniAb director Jennifer R. Cochran reported equity compensation-related transactions. On June 17, 20,000 Restricted Stock Units vested and were converted into 20,000 shares of Common Stock, bringing her direct holdings to 185,274 shares. She also received 40,000 stock options with a $2.03 exercise price and 20,000 new RSUs, each tied to one share of Common Stock, all vesting in full on the earlier of the next annual stockholder meeting or the first anniversary of the grant date.
OmniAb director Jennifer R. Cochran reported equity compensation-related transactions. On June 17, 20,000 Restricted Stock Units vested and were converted into 20,000 shares of Common Stock, bringing her direct holdings to 185,274 shares. She also received 40,000 stock options with a $2.03 exercise price and 20,000 new RSUs, each tied to one share of Common Stock, all vesting in full on the earlier of the next annual stockholder meeting or the first anniversary of the grant date.
OmniAb, Inc. director Steven C. Crouse reported equity compensation-related transactions with no share sales. He exercised derivative rights to acquire 20,000 shares of Common Stock, bringing his direct holdings to 33,333 shares. He also received 40,000 stock options at a $2.03 exercise price and 20,000 Restricted Stock Units, which vest based on the next annual stockholder meeting or the first anniversary of grant.
OmniAb, Inc. director Steven C. Crouse reported equity compensation-related transactions with no share sales. He exercised derivative rights to acquire 20,000 shares of Common Stock, bringing his direct holdings to 33,333 shares. He also received 40,000 stock options at a $2.03 exercise price and 20,000 Restricted Stock Units, which vest based on the next annual stockholder meeting or the first anniversary of grant.
OmniAb director Philip J. Gotwals reported equity compensation and vesting activity. He acquired 20,000 shares of Common Stock through the vesting and conversion of previously granted Restricted Stock Units and now holds 33,333 shares directly. He also received 40,000 new stock options with a $2.03 exercise price and 20,000 new RSUs, which vest in full on the earlier of the next annual stockholder meeting or the first anniversary of their grant dates.
OmniAb director Philip J. Gotwals reported equity compensation and vesting activity. He acquired 20,000 shares of Common Stock through the vesting and conversion of previously granted Restricted Stock Units and now holds 33,333 shares directly. He also received 40,000 new stock options with a $2.03 exercise price and 20,000 new RSUs, which vest in full on the earlier of the next annual stockholder meeting or the first anniversary of their grant dates.
OmniAb, Inc. director John L. Higgins reported compensation-related equity activity with no open-market trades. On June 17, 2026, he exercised 20,000 Restricted Stock Units into Common Stock, bringing his direct holdings to 2,962,320 shares. He also received 40,000 stock options at an exercise price of $2.03 per share, expiring on June 17, 2036, and a new grant of 20,000 RSUs, which vest in full on the earlier of the next annual stockholder meeting or the first anniversary of their grant.
OmniAb, Inc. director John L. Higgins reported compensation-related equity activity with no open-market trades. On June 17, 2026, he exercised 20,000 Restricted Stock Units into Common Stock, bringing his direct holdings to 2,962,320 shares. He also received 40,000 stock options at an exercise price of $2.03 per share, expiring on June 17, 2036, and a new grant of 20,000 RSUs, which vest in full on the earlier of the next annual stockholder meeting or the first anniversary of their grant.
OmniAb, Inc. director Steven Love reported equity compensation transactions and an option-related share acquisition. On June 17, 2026, he acquired 20,000 shares of Common Stock through the exercise or conversion of a derivative security, bringing his direct Common Stock holdings to 91,666 shares.
On the same date, he received a grant of 40,000 Stock Options with an exercise price of $2.03 per share, exercisable for Common Stock until June 17, 2036. He also received 20,000 Restricted Stock Units, each representing one share of Common Stock, and 20,000 RSUs vested into shares, leaving 13,334 RSUs outstanding. All activity reflects awards, vesting, and exercises; no open‑market purchases or sales were reported.
OmniAb, Inc. director Steven Love reported equity compensation transactions and an option-related share acquisition. On June 17, 2026, he acquired 20,000 shares of Common Stock through the exercise or conversion of a derivative security, bringing his direct Common Stock holdings to 91,666 shares.
On the same date, he received a grant of 40,000 Stock Options with an exercise price of $2.03 per share, exercisable for Common Stock until June 17, 2036. He also received 20,000 Restricted Stock Units, each representing one share of Common Stock, and 20,000 RSUs vested into shares, leaving 13,334 RSUs outstanding. All activity reflects awards, vesting, and exercises; no open‑market purchases or sales were reported.
OmniAb, Inc. reported the results of its 2026 Annual Meeting of Shareholders held on June 17, 2026. Shareholders elected two Class I directors to three-year terms ending at the 2029 Annual Meeting. Jennifer Cochran, Ph.D. received 57,948,696 votes for and 25,997,984 withheld, with 18,464,904 broker non-votes. Matthew W. Foehr received 82,231,849 votes for and 1,714,831 withheld, with 18,464,904 broker non-votes.
Shareholders also ratified the appointment of Ernst & Young LLP as OmniAb’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 102,163,551 votes for, 112,653 against, and 135,380 abstentions.
OmniAb, Inc. reported the results of its 2026 Annual Meeting of Shareholders held on June 17, 2026. Shareholders elected two Class I directors to three-year terms ending at the 2029 Annual Meeting. Jennifer Cochran, Ph.D. received 57,948,696 votes for and 25,997,984 withheld, with 18,464,904 broker non-votes. Matthew W. Foehr received 82,231,849 votes for and 1,714,831 withheld, with 18,464,904 broker non-votes.
Shareholders also ratified the appointment of Ernst & Young LLP as OmniAb’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 102,163,551 votes for, 112,653 against, and 135,380 abstentions.
OmniAb, Inc. reported sharply improved first-quarter 2026 results while remaining unprofitable. Revenue rose to $14.4 million from $4.2 million, driven mainly by a $10.0 million increase in license and milestone revenue. Service, xPloration and royalty revenue also grew modestly.
Operating expenses were broadly flat at $22.3 million, as lower research and development and general and administrative costs offset higher amortization of intangibles, including a $2.9 million impairment of certain legacy ion channel customer relationship assets. Net loss narrowed to $7.7 million from $18.2 million, or $0.06 per share versus $0.17 per share.
OmniAb ended March 31 2026 with $49.1 million in cash, cash equivalents and short-term investments and believes this balance can fund operations for at least the next 12 months. The company continues to scale its antibody discovery platform, with 107 active partners, 409 active programs and 3 approved partnered products.
OmniAb, Inc. reported sharply improved first-quarter 2026 results while remaining unprofitable. Revenue rose to $14.4 million from $4.2 million, driven mainly by a $10.0 million increase in license and milestone revenue. Service, xPloration and royalty revenue also grew modestly.
Operating expenses were broadly flat at $22.3 million, as lower research and development and general and administrative costs offset higher amortization of intangibles, including a $2.9 million impairment of certain legacy ion channel customer relationship assets. Net loss narrowed to $7.7 million from $18.2 million, or $0.06 per share versus $0.17 per share.
OmniAb ended March 31 2026 with $49.1 million in cash, cash equivalents and short-term investments and believes this balance can fund operations for at least the next 12 months. The company continues to scale its antibody discovery platform, with 107 active partners, 409 active programs and 3 approved partnered products.
OmniAb reported a much stronger first quarter of 2026, with revenue rising to $14.4 million from $4.2 million a year earlier, mainly on higher milestone revenue. Total GAAP costs and operating expenses were $22.3 million, roughly flat year over year, while non‑GAAP cash costs and operating expenses fell to $12.3 million from $14.7 million.
Net loss narrowed to $7.7 million, or $0.06 per share, compared with $18.2 million, or $0.17 per share, in the prior‑year quarter. OmniAb raised 2026 revenue guidance to $28–$33 million and now expects year‑end cash and cash equivalents of $33–$38 million, reflecting confidence in partner progress and its technology platform.
OmniAb reported a much stronger first quarter of 2026, with revenue rising to $14.4 million from $4.2 million a year earlier, mainly on higher milestone revenue. Total GAAP costs and operating expenses were $22.3 million, roughly flat year over year, while non‑GAAP cash costs and operating expenses fell to $12.3 million from $14.7 million.
Net loss narrowed to $7.7 million, or $0.06 per share, compared with $18.2 million, or $0.17 per share, in the prior‑year quarter. OmniAb raised 2026 revenue guidance to $28–$33 million and now expects year‑end cash and cash equivalents of $33–$38 million, reflecting confidence in partner progress and its technology platform.
OmniAb, Inc. will hold its 2026 Annual Meeting of Shareholders on June 17, 2026 at 8:00 a.m. Pacific Time in Emeryville, California. Shareholders of record as of April 23, 2026 will vote on electing two Class I directors and ratifying Ernst & Young LLP as auditor for 2026.
The proxy highlights a seven-member board with an independent chair, fully independent key committees, and restrictions on insider trading, pledging and hedging. It details executive pay, with CEO Matthew Foehr’s 2025 package combining salary, cash bonus and stock-based incentives tied to strategic, technology, portfolio, financial, and culture goals.
OmniAb, Inc. will hold its 2026 Annual Meeting of Shareholders on June 17, 2026 at 8:00 a.m. Pacific Time in Emeryville, California. Shareholders of record as of April 23, 2026 will vote on electing two Class I directors and ratifying Ernst & Young LLP as auditor for 2026.
The proxy highlights a seven-member board with an independent chair, fully independent key committees, and restrictions on insider trading, pledging and hedging. It details executive pay, with CEO Matthew Foehr’s 2025 package combining salary, cash bonus and stock-based incentives tied to strategic, technology, portfolio, financial, and culture goals.